全文获取类型
收费全文 | 1686176篇 |
免费 | 113988篇 |
国内免费 | 2420篇 |
专业分类
耳鼻咽喉 | 23527篇 |
儿科学 | 55762篇 |
妇产科学 | 47819篇 |
基础医学 | 256678篇 |
口腔科学 | 45477篇 |
临床医学 | 146069篇 |
内科学 | 323780篇 |
皮肤病学 | 36077篇 |
神经病学 | 126077篇 |
特种医学 | 65425篇 |
外国民族医学 | 410篇 |
外科学 | 257626篇 |
综合类 | 32892篇 |
现状与发展 | 2篇 |
一般理论 | 399篇 |
预防医学 | 123656篇 |
眼科学 | 38984篇 |
药学 | 128775篇 |
2篇 | |
中国医学 | 3358篇 |
肿瘤学 | 89789篇 |
出版年
2018年 | 16253篇 |
2016年 | 13862篇 |
2015年 | 15819篇 |
2014年 | 21642篇 |
2013年 | 32719篇 |
2012年 | 45899篇 |
2011年 | 49649篇 |
2010年 | 29122篇 |
2009年 | 27022篇 |
2008年 | 47277篇 |
2007年 | 51485篇 |
2006年 | 51773篇 |
2005年 | 50436篇 |
2004年 | 48762篇 |
2003年 | 47385篇 |
2002年 | 46397篇 |
2001年 | 74477篇 |
2000年 | 76443篇 |
1999年 | 64592篇 |
1998年 | 18252篇 |
1997年 | 16082篇 |
1996年 | 16365篇 |
1995年 | 15413篇 |
1994年 | 14488篇 |
1993年 | 13552篇 |
1992年 | 51587篇 |
1991年 | 51974篇 |
1990年 | 51551篇 |
1989年 | 50220篇 |
1988年 | 46743篇 |
1987年 | 45937篇 |
1986年 | 43578篇 |
1985年 | 41653篇 |
1984年 | 31046篇 |
1983年 | 26872篇 |
1982年 | 15562篇 |
1981年 | 13866篇 |
1979年 | 29578篇 |
1978年 | 20829篇 |
1977年 | 17777篇 |
1976年 | 17237篇 |
1975年 | 19348篇 |
1974年 | 22587篇 |
1973年 | 21770篇 |
1972年 | 20546篇 |
1971年 | 19294篇 |
1970年 | 18010篇 |
1969年 | 17143篇 |
1968年 | 16165篇 |
1967年 | 14331篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
M. M. Marchenko G. P. Kopyl’chuk I. A. Shmarakov O. V. Ketsa V. N. Kushnir 《Pharmaceutical Chemistry Journal》2006,40(6):296-297
The antitumor activity of 5-(5′,6′-benzocoumaro-3′-yl)methylaminouracil (BCMU) and its liposomal medicinal form was studied
in comparison to 5-fluorouracil (5-FU), a well-known antitumor drug widely used in oncological practice. The half-lethal dose
of BCMU is 14.8 ± 4.2 mg/kg, while the optimum effective dose of the drug is 6 mg/kg. In this dose, BCMU combines low toxicity
with significant antitumor activity, which is manifested by increased tumor growth inhibition (TGI) at a 19% increase in the
lifetime (LT) of experimental animals. The antitumor activity of the liposomal form of BCMU is quantitatively and qualitatively
superior to that of the nonmodified compound and 5-FU, which is manifested by the most pronounced TGI value and by a significant
LT increase.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 6, pp. 6–7, June, 2006. 相似文献
993.
Noriyoshi Kurihara Hua Zhou Sakamuri V Reddy Veronica Garcia Palacios Mark A Subler David W Dempster Jolene J Windle G David Roodman 《Journal of bone and mineral research》2006,21(3):446-455
We targeted the MVNP gene to the OCL lineage in transgenic mice. These mice developed abnormal OCLs and bone lesions similar to those found in Paget's patients. These results show that persistent expression of MVNP in OCLs can induce pagetic-like bone lesions in vivo. INTRODUCTION: Paget's disease (PD) of bone is the second most common bone disease. Both genetic and viral factors have been implicated in its pathogenesis, but their exact roles in vivo are unclear. We previously reported that transfection of normal human osteoclast (OCL) precursors with the measles virus nucleocapsid (MVNP) or measles virus (MV) infection of bone marrow cells from transgenic mice expressing a MV receptor results in formation of pagetic-like OCLs. MATERIALS AND METHODS: Based on these in vitro studies, we determined if the MVNP gene from either an Edmonston-related strain of MV or a MVNP gene sequence derived from a patient with PD (P-MVNP), when targeted to cells in the OCL lineage of transgenic mice with the TRACP promoter (TRACP/MVNP mice), induced changes in bone similar to those found in PD. RESULTS: Bone marrow culture studies and histomorphometric analysis of bones from these mice showed that their OCLs displayed many of the features of pagetic OCLs and that they developed bone lesions that were similar to those in patients with PD. Furthermore, IL-6 seemed to be required for the development of the pagetic phenotype in OCLs from TRACP/MVNP mice. CONCLUSIONS: These results show that persistent expression of the MVNP gene in cells of the OCL lineage can induce pagetic-like bone lesions in vivo. 相似文献
994.
Chang Y Jung Hyo S Choi Jin S Ju Hyo S Park Tae G Kwon Yong C Bae Dong K Ahn 《The journal of pain》2006,7(10):747-756
The present study investigated the role of central metabotropic glutamate receptors (mGluRs) in interleukin-1beta (IL-1beta)-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Experiments were carried out on male Sprague-Dawley rats weighing 230 to 280 g. After administration of 0.01, 0.1, 1, or 10 pg of IL-1beta into a subcutaneous area of the vibrissa pad, we examined the withdrawal behavioral responses produced by 10 successive trials of an air-puff ramp pressure applied ipsilaterally or contralaterally to the IL-1beta injection site. Subcutaneous injection of IL-1beta produced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Intracisternal administration of CPCCOEt, a mGluR1 antagonist, or MPEP, a mGluR5 antagonist, reduced IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. Intracisternal administration of APDC, a group II mGluR agonist, or L-AP4, a group III mGluR agonist, reduced both IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. The antiallodynic effect, induced by APDC or L-AP4, was blocked by intracisternal pretreatment with LY341495, a group II mGluR antagonist, or CPPG, a group III mGluR antagonist. These results suggest that groups I, II, and III mGluRs differentially modulated IL-1beta-induced mechanical allodynia, as well as mirror-image mechanical allodynia, in the orofacial area. PERSPECTIVE: Central group I mGluR antagonists and groups II and III mGluR agonists modulate IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Therefore, the central application of group I mGluR antagonists or groups II and III mGluR agonists might be of therapeutic value in treating pain disorder. 相似文献
995.
This study presents the case of a patient with necrobiosis or necrosing fascitis of the inguinal region, secondary to a complicated
Amyand’s hernia with a concomitant ipsilateral Richter’s hernia. The patient was treated with open trans-abdominal surgery
and hernia repair through the pre-peritoneal approach, plus anti-microbians, and thrice-daily wound cleansing and dressings
to the inguinal region. Evolution was satisfactory. There are no reports in the literature of a case such as this. 相似文献
996.
Priv.-Doz. Dr. Rüdiger Dissmann Joachim Schröder MD PhD Prof. Dr. med. Heinz Völler Prof. Dr. med. Steffen Behrens 《Clinical research in cardiology》2006,95(4):241-243
Summary During pacemaker implantation in a patient with permanent atrial fibrillation, it remained impossible to advance a passive
fixation lead with fins through the right atrium. However, a lead with a retractable screw easily passed the right atrium
and was positioned in the right ventricle. Transesophageal echocardiography revealed an extensive net–like perforated Eustachian
valve within the right atrium that had caused entrapment of the anchor fins during lead implantation. Remnants of embryonal
structures within the right atrium should be considered a rare possible barrier during pacemaker implantation. 相似文献
997.
Design of Case-controls Studies with Unscreened Controls 总被引:2,自引:0,他引:2
Traditionally in genetic case‐control studies controls have been screened to exclude subjects with a personal history of illness. This control group has the advantage of optimal power to detect loci involved in illness, but requires more work and may incur substantial cost in recruitment. An alternative approach to screening is to use unscreened controls sampled from the general population. Such controls are generally plentiful and inexpensive, but in general there is a risk that some may have the same disease as the cases, which will reduce power to detect associations. We have quantified the extent of this power loss, and produced mathematical formulae for the number of unscreened controls necessary to achieve the same power as a fixed sample of screened controls. The effect of using unscreened controls will also depend on the ratio of the number of screened controls to cases specified in the original study design, and this is also investigated. We have also investigated the cost‐benefits of the screened and unscreened approaches, according to variation in the relative costs of sampling screened and unscreened controls, together with genotyping costs. We have, thus, identified the range of situations in which using unscreened controls is a cost‐effective alternative to the screened control method and could be considered when designing a study. In many of the typical, real‐world situations in complex genetics, the use of unscreened controls is potentially cost‐effective and can, in general, be considered for disorders with population prevalence Kp < 0.2. With the steady reduction in genotyping costs and the availability of common sets of “population controls” this design is likely to become increasingly cost effective. 相似文献
998.
J. Jayabharathi V. Thanikachalam A. Thangamani M. Padmavathy 《Medicinal chemistry research》2007,16(6):266-279
Some novel N(1)-arylidene-N(2)-cis-2,6-diphenyltetrahydrothiopyran-4-one azine derivatives were synthesised and their antibacterial activity against Streptococcus faecalis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and antifungal activity against Candida-6, Candida-51, Aspergillus niger, and Aspergillus flavus were evaluated. 相似文献
999.
J. P. G. Kaajan 《Pharmacy World & Science》1989,11(4):112-117
The general management of patients with chronic obstructive pulmonary disease and asthma is discussed. Pathophysiological mechanisms of bronchial obstruction and inflammation are briefly described. The importance of preventive measures is emphasized. Medicine prescribed in chronic obstructive pulmonary disease and asthma, their relative place in treatment schedules and route of administration are reviewed. Finally, the importance of maximal bronchodilatation in exacerbations is stressed and the few indications for antibiotic treatment are discussed. 相似文献
1000.
Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 23, No. 5, pp. 540–549, May, 1989. 相似文献